Cargando…
Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392728/ https://www.ncbi.nlm.nih.gov/pubmed/37489353 http://dx.doi.org/10.1080/21645515.2023.2235957 |
| _version_ | 1785083020066160640 |
|---|---|
| author | Mungmunpuntipantip, Rujitika Wiwanitkit, Viroj |
| author_facet | Mungmunpuntipantip, Rujitika Wiwanitkit, Viroj |
| author_sort | Mungmunpuntipantip, Rujitika |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10392728 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Taylor & Francis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103927282023-08-02 Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment Mungmunpuntipantip, Rujitika Wiwanitkit, Viroj Hum Vaccin Immunother Coronavirus Taylor & Francis 2023-07-25 /pmc/articles/PMC10392728/ /pubmed/37489353 http://dx.doi.org/10.1080/21645515.2023.2235957 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
| spellingShingle | Coronavirus Mungmunpuntipantip, Rujitika Wiwanitkit, Viroj Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment |
| title | Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment |
| title_full | Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment |
| title_fullStr | Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment |
| title_full_unstemmed | Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment |
| title_short | Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment |
| title_sort | homologous or heterologous immunization regimens against sars-cov-2 after two doses of inactivated covid-19 vaccine: comment |
| topic | Coronavirus |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392728/ https://www.ncbi.nlm.nih.gov/pubmed/37489353 http://dx.doi.org/10.1080/21645515.2023.2235957 |
| work_keys_str_mv | AT mungmunpuntipantiprujitika homologousorheterologousimmunizationregimensagainstsarscov2aftertwodosesofinactivatedcovid19vaccinecomment AT wiwanitkitviroj homologousorheterologousimmunizationregimensagainstsarscov2aftertwodosesofinactivatedcovid19vaccinecomment |